Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 11,255 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Myelomeningocele
Interventions: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix, Untreated contemporaneous cohort; Biological · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 19 Weeks to 25 Weeks
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Atopic Dermatitis
Interventions: Oregano extract cream, Hydrocortisone; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: MPS IVA, MPS VI
Interventions: Vosoritide Injection [Voxzogo]; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Years to 10 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Oakland, California

Conditions: Age-Related Osteoporosis
Interventions: Sample collection for gene expression; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Duchenne Muscular Dystrophy, Cardiomyopathy
Interventions: Allogeneic Cardiosphere-Derived Cells (CAP-1002); Drug
Lead sponsor: Capricor Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Gainesville, Florida • Cincinnati, Ohio

Conditions: Vaso-occlusive Pain Episodes
Interventions: Arginine, Placebo; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 3 Years to 21 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Oakland, California

Conditions: Chronic Granulomatous Disease
Interventions: Stem cell transplantation; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sickle Cell Disease, Pain Management
Interventions: Hypnosis, Control; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Down Syndrome
Interventions: 2 months of drumming lessons given by a professional drummer with extensive experience working with children with Down syndrome, Lessons after measurement; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 7 Years to 15 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Premature; Infant, Light-for-dates, Enteral Feeding Intolerance
Interventions: Exclusive Enteral Nutrition, Progressive Enteral Nutrition; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Hour to 48 Hours
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Smith-Magenis Syndrome (SMS)
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month to 115 Years
Enrollment: 593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Childhood Kidney Neoplasm, Stage I Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions: Low dose LX2006, Mid Dose LX2006, High Dose LX2006; Genetic
Lead sponsor: Lexeo Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Rochester, Minnesota

Conditions: Atopic Dermatitis (AD)
Interventions: BFB759, Placebo; Biological · Drug
Lead sponsor: Bluefin Biomedicine, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Encino, California • Huntington Beach, California + 40 more

Conditions: Constipation Chronic Idiopathic, Cystic Fibrosis
Interventions: Maralixibat 9.5 MG/ML [Livmarli]; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 48
States / cities: Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more

Conditions: Cystic Fibrosis, Pediatrics
Interventions: Sputum; Biological
Lead sponsor: University of Miami; Other
Eligibility: Up to 18 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Primary Immunodeficiency
Interventions: IgPro; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Litchfield Park, Arizona • Scottsdale, Arizona • Centennial, Colorado + 5 more

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers; Drug · Device
Lead sponsor: Boston University; Other
Eligibility: 3 Months to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cirrhosis, Congenital Heart Disease
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sickle Cell Anemia
Interventions: Not listed
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 8 Years to 21 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, β-Adrenergic cocktail, Pilocarpine Nitrate 5%, Macroduct sweat stimulator; Drug · Device
Lead sponsor: Richard Barry Moss; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI

Genetic Regulators of Bone Health That Are Unique to Vertebral Bone

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial

Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease

Outcomes of Children With Congenital Single Ventricle Heart

Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease

Drumming Lessons' Influence on Children With Down Syndrome

Exclusive Enteral Nutrition in Preterm Neonates

Natural History Study of Smith-Magenis Syndrome

Gene Analysis in Studying Susceptibility to Wilms Tumor

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Maralixibat in Patients With Cystic Fibrosis and Constipation

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study

Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia

(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?